Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO
Adaptimmune Therapeutics plc - American Depositary Shares (ADAP)
Last adaptimmune therapeutics plc - american depositary shares earnings: 5/9 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.adaptimmune.com/phoenix.zhtml?c=253991&p=irol-newsarticle&id=2255800
Company Research
Source: GlobeNewswire
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented updated data from patients with synovial sarcoma who were treated in the ongoing Phase 1 trial with SPEAR T-cells targeting MAGE-A4 (ADP-A2M4). The oral presentation by Brian Van Tine, MD, PhD of Washington University in St. Louis, occurred earlier today at the European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain. “These data demonstrate a clear benefit of SPEAR T-cells for this population of patients with synovial sarcoma. These results are truly meaningful in this rare and deadly disease because patients with advanced synovial sarcoma have very few treatment options,” said Elliot Norry, Adaptimmune’s interim Chief Medical Officer. “These data and the recent FDA orphan drug designation for ADP-A2M4 in sarcoma are important positive steps to expedite further development. We recently st
Show less
Read more
Impact Snapshot
Event Time:
ADAP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADAP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADAP alerts
High impacting Adaptimmune Therapeutics plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ADAP
News
- Adaptimmune: Huge Opportunity Amid Their Setback With Genentech [Seeking Alpha]Seeking Alpha
- Garry Menzel joins GHO Capital as Operating Partner [Yahoo! Finance]Yahoo! Finance
- Adaptimmune (ADAP) Down on End of Collaboration With Roche [Yahoo! Finance]Yahoo! Finance
- Adaptimmune falls as Roche strategic collaboration ends [Seeking Alpha]Seeking Alpha
- Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated [Yahoo! Finance]Yahoo! Finance
ADAP
Sec Filings
- 4/22/24 - Form ARS
- 4/12/24 - Form 8-K
- 4/11/24 - Form DEF
- ADAP's page on the SEC website